Biologics
- 457.855
- -6.321-1.36%
Significant layoffs? Remegen responds: It is a normal business optimization. The recently adapted indication for Taitsip will be applied for listing.
①Regarding the online rumors of layoffs, the secretary of the board of directors of Remegen stated that the company has been sorting out its business since last year, and the optimization of positions and personnel is based on work needs, without a rigid proportion; ②The other party revealed that the severe myasthenia gravis indication of the targeted drug Taituxip is expected to apply for market approval soon. However, Taituxip is facing multiple competitions in the market.
Jiangsu Sihuan Bioengineering's actual controller has been given a "red card" for lifetime market ban again, and Lu Keping and his son are expected to be fined nearly 30 million yuan. Read the announcement quickly.
①Due to the ST Weichuang suspected of illegal disclosure of information, jiangsu sihuan bioengineering's ultimate controller Lu Keping and the company's director Lu Yu father and son received a "sky-high" fine. ②In this case, Lu Keping has issues such as keeping the identity of the ultimate controller "secret" and has once again been subjected to a lifetime ban from the securities market. ③According to the pre-notification of administrative penalties, Lu Keping and his son were fined a total of nearly 30 million yuan.
Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Is the GLP-1 pipeline progressing slowly? Gan & Lee Pharmaceuticals: GZR18 has the potential for superior weight reduction efficacy compared to multi-target drugs | Live coverage of the earnings conference.
At the earnings conference, the management of Gan & Lee Pharmaceuticals emphasized that the price regression of the company's insulin products in the follow-up volume procurement has driven the performance. In the face of doubts about the progress of GLP-1 pipeline research and competitiveness, Dou Kai, the General Manager of Gan & Lee Pharmaceuticals, stated that GZR18 injection has a weight loss effect that exceeds exenatide and dulaglutide, and has the potential to be superior to multi-target GLP-1RA drugs in weight loss efficacy.
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.
Kangle Guardian H1 is still losing money, or hopes to rely on the launch of the trivalent HPV vaccine. Interpretation of the financial report.
①H1 Kang Le Wei Shi's revenue declined year-on-year while still in a state of loss, and it is expected that the loss will continue in the future. ②Currently, Kang Le Wei Shi's trivalent HPV vaccine has the fastest research and development progress and may become the company's first commercial product.
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Behind the "cliff-like" decline in performance of Beijing Wantai Biological: vaccine business revenue decreased by more than 80% | interpretations
①The main reason for the significant decline in the performance of beijing wantai biological pharmacy enterprise's H1 is the decrease in sales revenue of the bivalent HPV vaccine. ②The revenue of the company's diagnostic division exceeded the vaccine division, while overseas revenue saw a certain year-on-year growth. ③The production conditions for the commercialization of the nonavalent HPV vaccine of the company are in place, and the listing application is progressing according to plan.
2024 Financial Report | Insulin Low Price Competition, Gan Li Pharmaceutical's Gains and Losses
Go out to sea
2024 Financial Report | Profit growth hit its lowest level in 10 years. Is Changchun Gaoxin's growth hormone ceiling here?
The time for the “first strain of growth hormone” to slow down has arrived. On March 20, Changchun Hi-Tech (000661.SZ) released its 2023 financial report, showing that current revenue and net profit to mother were 14.566 billion yuan and 4.532 billion yuan respectively, up 15.35% and 9.47% year-on-year respectively. This net profit growth rate to mother hit a record low since 2014. On March 20, Changchun Hi-Tech closed down 2.57%. Specifically, the current revenue and net revenue of Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), the core subsidiary responsible for growth hormone under Changchun Hi-Tech
The first “North + Hong Kong” order is here: the nine-valent HPV vaccine vendor Leisure Guard submits the Hong Kong Stock Exchange
First to eat crabs
Taizhou torrential rain A-share impact tracking: Jindick may have “no grain collection”, and the responses of more than 10 listed companies have no impact
The extreme weather during the typhoon season is having a potential impact on the production and operation activities of some listed companies. On July 17, the Taizhou Meteorological Observatory issued an orange warning signal for rainstorms, initiating a level-IV emergency response for flood control. Prior to that, beginning on July 6, rare heavy rain began to occur in the north-central region of the region. Whether this will adversely affect local companies is receiving market attention. According to Wind data, a total of 16 A-share companies have registered addresses in Taizhou. Some local companies have issued announcements confirming that production and operation have been impacted. On July 15, influenza vaccine company Kim Dick (688670.SH
Impacted by torrential rain: Kim Dick's revenue for the third quarter is likely to return to zero, and it has already fallen to a halt by 20cm intraday
A torrential rain in Taizhou, Jiangsu thundered Jin Dick (688670.SH), a company listed on the A-share Science and Technology Innovation Board. On July 14, Jindik issued an announcement stating that due to heavy rain in the Taizhou Pharmaceutical High-tech Zone (Gaogang District) where the company is located, the company's plant was flooded, and the production environment in some workshops was affected by water seepage. After continuous environmental monitoring and comprehensive assessment, the company decided to temporarily stop production of the influenza vaccine workshop on July 15. Kim Dick said that all of the company's revenue comes from the quadrivalent influenza vaccine. The production and sales of influenza vaccines have obvious seasonal characteristics. Every year, September-December is the peak season for influenza vaccine sales. Because of the flow
Aligos Therapeutics Announced Friday A Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos' Oligonucleotide Platform For Treatment Of Liver Diseases
Aligos Therapeutics and Xiamen Amoytop Biotech Join Hands for the Treatment of Liver Diseases
With EPS Growth And More, Chongqing Zhifei Biological Products (SZSE:300122) Makes An Interesting Case
Market Chatter: SoftBank, Others in Talks to Raise Up to $300 Million For Chinese Vaccine Maker Suzhou Abogen
China Resources Pharma Concludes Purchase of Controlling Stake in Boya Bio